vs
Side-by-side financial comparison of Sight Sciences, Inc. (SGHT) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $12.1M, roughly 1.7× TRANSCONTINENTAL REALTY INVESTORS INC). TRANSCONTINENTAL REALTY INVESTORS INC runs the higher net margin — 68.8% vs -20.4%, a 89.2% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs 2.3%). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs 0.7%).
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.
SGHT vs TCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.4M | $12.1M |
| Net Profit | $-4.2M | $8.3M |
| Gross Margin | 87.3% | — |
| Operating Margin | -18.0% | -28.9% |
| Net Margin | -20.4% | 68.8% |
| Revenue YoY | 6.9% | 2.3% |
| Net Profit YoY | 64.9% | 7577.8% |
| EPS (diluted) | $-0.07 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.4M | $12.1M | ||
| Q3 25 | $19.9M | $12.8M | ||
| Q2 25 | $19.6M | $12.2M | ||
| Q1 25 | $17.5M | $12.0M | ||
| Q4 24 | $19.1M | $11.8M | ||
| Q3 24 | $20.2M | $11.6M | ||
| Q2 24 | $21.4M | $11.8M | ||
| Q1 24 | $19.3M | $11.9M |
| Q4 25 | $-4.2M | $8.3M | ||
| Q3 25 | $-8.2M | $724.0K | ||
| Q2 25 | $-11.9M | $169.0K | ||
| Q1 25 | $-14.2M | $4.6M | ||
| Q4 24 | $-11.8M | $108.0K | ||
| Q3 24 | $-11.1M | $1.7M | ||
| Q2 24 | $-12.3M | $1.5M | ||
| Q1 24 | $-16.3M | $2.5M |
| Q4 25 | 87.3% | — | ||
| Q3 25 | 86.4% | — | ||
| Q2 25 | 84.8% | — | ||
| Q1 25 | 86.2% | — | ||
| Q4 24 | 86.8% | — | ||
| Q3 24 | 83.9% | — | ||
| Q2 24 | 85.8% | — | ||
| Q1 24 | 85.5% | — |
| Q4 25 | -18.0% | -28.9% | ||
| Q3 25 | -39.7% | -10.9% | ||
| Q2 25 | -59.6% | -6.8% | ||
| Q1 25 | -79.2% | -5.3% | ||
| Q4 24 | -62.5% | -14.3% | ||
| Q3 24 | -55.7% | -14.4% | ||
| Q2 24 | -59.2% | -9.2% | ||
| Q1 24 | -76.4% | -11.2% |
| Q4 25 | -20.4% | 68.8% | ||
| Q3 25 | -41.0% | 5.6% | ||
| Q2 25 | -61.0% | 1.4% | ||
| Q1 25 | -80.8% | 38.5% | ||
| Q4 24 | -62.1% | 0.9% | ||
| Q3 24 | -54.9% | 14.7% | ||
| Q2 24 | -57.7% | 12.7% | ||
| Q1 24 | -84.4% | 21.4% |
| Q4 25 | $-0.07 | $0.97 | ||
| Q3 25 | $-0.16 | $0.08 | ||
| Q2 25 | $-0.23 | $0.02 | ||
| Q1 25 | $-0.28 | $0.53 | ||
| Q4 24 | $-0.23 | $0.01 | ||
| Q3 24 | $-0.22 | $0.20 | ||
| Q2 24 | $-0.25 | $0.17 | ||
| Q1 24 | $-0.33 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $92.0M | $89.0M |
| Total DebtLower is stronger | $42.4M | $210.8M |
| Stockholders' EquityBook value | $63.9M | $846.7M |
| Total Assets | $115.3M | $1.1B |
| Debt / EquityLower = less leverage | 0.66× | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $92.0M | $89.0M | ||
| Q3 25 | $92.4M | $82.7M | ||
| Q2 25 | $101.5M | $73.5M | ||
| Q1 25 | $108.8M | $88.6M | ||
| Q4 24 | $120.4M | $99.7M | ||
| Q3 24 | $118.6M | $131.6M | ||
| Q2 24 | $118.2M | $127.5M | ||
| Q1 24 | $127.3M | $130.8M |
| Q4 25 | $42.4M | $210.8M | ||
| Q3 25 | $42.4M | $223.5M | ||
| Q2 25 | $42.4M | $212.4M | ||
| Q1 25 | $42.4M | $198.2M | ||
| Q4 24 | $40.0M | $181.9M | ||
| Q3 24 | $37.1M | $180.3M | ||
| Q2 24 | $35.0M | $177.4M | ||
| Q1 24 | $35.0M | $178.3M |
| Q4 25 | $63.9M | $846.7M | ||
| Q3 25 | $64.3M | $838.4M | ||
| Q2 25 | $70.0M | $837.7M | ||
| Q1 25 | $77.6M | $837.3M | ||
| Q4 24 | $87.5M | $832.3M | ||
| Q3 24 | $95.0M | $832.2M | ||
| Q2 24 | $101.6M | $830.4M | ||
| Q1 24 | $109.2M | $828.9M |
| Q4 25 | $115.3M | $1.1B | ||
| Q3 25 | $116.3M | $1.1B | ||
| Q2 25 | $122.0M | $1.1B | ||
| Q1 25 | $129.7M | $1.1B | ||
| Q4 24 | $142.8M | $1.1B | ||
| Q3 24 | $143.6M | $1.1B | ||
| Q2 24 | $149.7M | $1.0B | ||
| Q1 24 | $155.6M | $1.0B |
| Q4 25 | 0.66× | 0.25× | ||
| Q3 25 | 0.66× | 0.27× | ||
| Q2 25 | 0.61× | 0.25× | ||
| Q1 25 | 0.55× | 0.24× | ||
| Q4 24 | 0.46× | 0.22× | ||
| Q3 24 | 0.39× | 0.22× | ||
| Q2 24 | 0.34× | 0.21× | ||
| Q1 24 | 0.32× | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.8M | $-2.9M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -9.7% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | — | -0.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.8M | $-2.9M | ||
| Q3 25 | $-8.7M | $8.2M | ||
| Q2 25 | $-7.5M | $-2.9M | ||
| Q1 25 | $-11.6M | $-7.4M | ||
| Q4 24 | $-3.5M | $1.3M | ||
| Q3 24 | $362.0K | $13.7M | ||
| Q2 24 | $-9.5M | $-511.0K | ||
| Q1 24 | $-9.8M | $3.9M |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $-8.9M | — | ||
| Q2 25 | $-7.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-3.6M | — | ||
| Q3 24 | $311.0K | — | ||
| Q2 24 | $-9.5M | — | ||
| Q1 24 | $-9.9M | — |
| Q4 25 | -9.7% | — | ||
| Q3 25 | -44.7% | — | ||
| Q2 25 | -39.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -18.9% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | -44.7% | — | ||
| Q1 24 | -51.4% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | -0.35× | ||
| Q3 25 | — | 11.28× | ||
| Q2 25 | — | -17.24× | ||
| Q1 25 | — | -1.61× | ||
| Q4 24 | — | 12.13× | ||
| Q3 24 | — | 8.03× | ||
| Q2 24 | — | -0.34× | ||
| Q1 24 | — | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
TCI
Segment breakdown not available.
